|
| Status |
Public on Mar 19, 2024 |
| Title |
Expression data from T-cell Acute Lymphoblastic Leukemia (T-ALL) patient-derived xenograft treated with anti-CD3 mAbs. |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by array
|
| Summary |
T-cell acute lymphoblastic leukemia is an aggressive hematological malignancy treated with chemotherapy and has a poor prognosis. In previous studies, we demonstrated that T cell receptor (TCR)-induced negative selection is highly effective in combating T-ALL in mouse models. Moreover, targeting the TCR of diagnostic T-ALL-derived PDX with anti-hCD3 (aCD3) mAb OKT3 or the clinically relevant aCD3 mAb Teplizumab resulted in leukemic cell death, regression of leukemia, and improved host survival. The objective of the present experiment is to uncover the molecular mechanisms responsible for the anti-leukemic properties of the anti-CD3 mAbs OKT3 and Teplizumab in a T-ALL PDX model.
We compare the transcriptomic profiles of FACS-sorted T-ALL cells extracted from T-ALL patient-derived xenograft (PDX) treated for 6h with isotype control antibody IgG2a or OKT3 mAb or Teplizumab mAb.
|
| |
|
| Overall design |
The transcriptome of 9 T-cell Acute Lymphoblastic Leukemia (T-ALL) patient-derived xenograft models were analyzed using Affymetrix GeneChip Human Gene 2.0 ST arrays.
|
| |
|
| Contributor(s) |
Avila Avila A, Zaniboni B, Druillennec S, Ghysdael J, Tran Quang C |
| Citation(s) |
38437728 |
| Submission date |
Aug 07, 2023 |
| Last update date |
Mar 20, 2024 |
| Contact name |
Christine Tran Quang |
| E-mail(s) |
christine.tran-quang@curie.fr
|
| Organization name |
Institut Curie
|
| Street address |
Bat 110 centre universitaire
|
| City |
Orsay |
| ZIP/Postal code |
91405 |
| Country |
France |
| |
|
| Platforms (1) |
| GPL16686 |
[HuGene-2_0-st] Affymetrix Human Gene 2.0 ST Array [transcript (gene) version] |
|
| Samples (9)
|
| GSM7689159 |
human T_ALL PDX from mouse 1 treated with control IgG2a |
| GSM7689160 |
human T_ALL PDX from mouse 2 treated with control IgG2a |
| GSM7689161 |
human T_ALL PDX from mouse 3 treated with control IgG2a |
| GSM7689162 |
human T_ALL PDX from mouse 4 treated with OKT3 mAb |
| GSM7689163 |
human T_ALL PDX from mouse 5 treated with OKT3 mAb |
| GSM7689164 |
human T_ALL PDX from mouse 6 treated with OKT3 mAb |
| GSM7689165 |
human T_ALL PDX from mouse 7 treated with Teplizumab mAb |
| GSM7689166 |
human T_ALL PDX from mouse 8 treated with Teplizumab mAb |
| GSM7689167 |
human T_ALL PDX from mouse 9 treated with Teplizumab mAb |
|
| Relations |
| BioProject |
PRJNA1003057 |
Less...
More...